Trupanion, Inc. (NASDAQ:TRUP) Director Sells $105,340.00 in Stock

Trupanion, Inc. (NASDAQ:TRUP) Director Murray B. Low sold 2,000 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $52.67, for a total transaction of $105,340.00. Following the completion of the sale, the director now directly owns 131,513 shares of the company’s stock, valued at $6,926,789.71. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Trupanion Trading Up 3.2 %

NASDAQ TRUP opened at $50.49 on Friday. Trupanion, Inc. has a 1-year low of $19.69 and a 1-year high of $57.90. The business has a 50 day simple moving average of $47.39 and a two-hundred day simple moving average of $37.21. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.63 and a current ratio of 1.66.

Trupanion (NASDAQ:TRUP) last announced its earnings results on Wednesday, October 30th. The financial services provider reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.09. The firm had revenue of $327.50 million for the quarter, compared to analysts’ expectations of $321.79 million. Trupanion had a negative net margin of 1.08% and a negative return on equity of 4.36%. The business’s revenue was up 14.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.10) EPS. On average, sell-side analysts anticipate that Trupanion, Inc. will post -0.23 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TRUP has been the subject of a number of recent analyst reports. Evercore ISI upgraded shares of Trupanion to a “strong-buy” rating in a research report on Friday, August 9th. William Blair assumed coverage on Trupanion in a research note on Friday, July 19th. They issued an “outperform” rating for the company. Bank of America boosted their price objective on Trupanion from $47.00 to $56.00 and gave the company a “buy” rating in a research report on Friday, September 20th. Piper Sandler increased their target price on Trupanion from $45.00 to $57.00 and gave the stock a “neutral” rating in a research report on Thursday, October 31st. Finally, Northland Securities lifted their target price on Trupanion from $45.00 to $50.00 and gave the company a “market perform” rating in a research note on Thursday, October 31st. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Trupanion presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.67.

Institutional Investors Weigh In On Trupanion

Institutional investors have recently modified their holdings of the stock. ProShare Advisors LLC raised its holdings in Trupanion by 33.8% during the 1st quarter. ProShare Advisors LLC now owns 121,417 shares of the financial services provider’s stock valued at $3,352,000 after buying an additional 30,645 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Trupanion in the first quarter valued at $473,000. Renaissance Technologies LLC purchased a new stake in shares of Trupanion in the second quarter valued at $4,739,000. Marshall Wace LLP lifted its holdings in shares of Trupanion by 11.9% in the 2nd quarter. Marshall Wace LLP now owns 1,094,589 shares of the financial services provider’s stock worth $32,181,000 after acquiring an additional 116,496 shares during the last quarter. Finally, Connors Investor Services Inc. boosted its stake in shares of Trupanion by 31.3% during the 2nd quarter. Connors Investor Services Inc. now owns 113,567 shares of the financial services provider’s stock worth $3,339,000 after purchasing an additional 27,042 shares during the period.

Trupanion Company Profile

Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians.